- CiteAb Award highlights Company’s relentless efforts to combat global life sciences reproducibility crisis
Cambridge, UK, 6 March 2020- Today, Abcam, the global life sciences company that identifies, develops, and distributes high-quality biological reagents and tools, announced that it was the recipient of the 2020 CiteAb Award for Antibody supplier succeeding in knockout (KO) validation. This new category recognizes the company with the largest percentage of KO validated antibodies in the current CiteAb listings.
The demand for validation testing that demonstrates antibody specificity continues to dominate the industry, as the quality of life sciences reagents like antibodies1 continues to be linked to the global reproducibility crisis. To further accelerate the use of KO testing across the industry, in January Abcam launched its ready-to-use gene-edited KO cell lines, which allow researchers to confidently carry out antibody validation in their most commonly-used protein applications - without the need to first establish a KO cell line.
Dr Alejandra Solache, VP New Product Development, Abcam, commented: ““We are thrilled to be recognized with the award for ‘Antibody supplier succeeding in knockout (KO) validation.’ Abcam’s dedication to high quality, combined with our scale and influence, puts us in a unique leadership position with significant responsibility within the industry. The scale of our initiatives, and the breadth and depth of our reagent portfolio, means that when we introduce a validation technique like the use of KO models as negative controls, it can benefit thousands of researchers globally. It also helps set industry standards in antibody validation. At Abcam, our mission is to help scientists achieve their discoveries faster, and providing reagents that work the first time, every time, is key to fulfilling this goal.“
Dr Andrew Chalmers, CEO, CiteAb, said: “Here at CiteAb we talk regularly about the progress being made in the field of antibody validation. This year we wanted to recognize suppliers who are making excellent use of knockout validation technology, while also celebrating adding validation information to our listing. Congratulations to the team at Abcam for winning this very meaningful award.“
The CiteAb Awards were founded in 2014 to recognize life sciences providers making a significant impact to the industry in terms of antibody data, validation testing and reproducibility.
1. Bradbury A. et al., 2015. Reproducibility: Standardize antibodies used in research. Nature. 518(7537): pp 27-9.
Notes to Editors
About Abcam plc
As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.
Abcam partners with life science organizations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company’s proprietary discovery platforms and world-leading, antibody expertise.
By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company’s pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products.
With eleven sites globally, many of Abcam’s 1,100 strong team are located in the world’s leading life science research hubs, complementing a global network of services and support.
Dr Priya Kalia
External Communications, Abcam